We analyzed the distribution of nasal erectile tissue by reviewing five sets of magnetic resonance imaging scans that were obtainedpre-andpost-decongestion. We found that cavernous tissues were located at three sites: the inferior turbinate, the middle turbinate, and the nasal septum. This study reaffirms the findings of previous studies that were performed with other modalities such as computed tomography scanning and cadaver dissections.
Introduction
The erectile mucosa of the nose plays an important regulatory role. By expanding and shrinking, the mucosa alters the caliber of the air passages and, consequently, the speed and volume of airflow.' It also regulates the amount of warming and humidification of the inspired air. It is commonly assumed that erectile tissue is located mainly in the nasal turbinates, but there are only a few studies that have sought to identify the anatomic distribution of these cavernous tissues in the nose.
Cole et a1 specifically sought to identify these areas with computed tomography (CT).* Using decongestion and artificial congestion, they determined that the erectile mucosa was located in three areas: the middle turbinate, the body of the inferior turbinate, and the anterior septal region. Cole and colleagues noted that the cavernous tissue in the anterior septal region and in the anterior tip Chicago.
of the inferior turbinate contributes to the constriction of the nasal valve area. Gwaltney et a1 performed a CT study of the common cold.) They noted the presence of engorged turbinates and thickened walls in the nasal passages, but they did not mention in which specific areas of the nose they were located. Magnetic resonance imaging (MRI) may be used to depict the anatomy of the nasal cavities without any known adverse effects on the subject. The use of MRI in clinical rhinology remains limited because of its inability to directly visualize bone. However, MRI is useful in imaging mucosal structures that are important factors in nasal patency and volume.
Webber et a1 showed that the nasal cycle was present in a dog by identifying on MRI periodic engorgement of the erectile tissue surrounding the t~rbinates.~ Kennedy et a1 studied physiologic mucosal changes during the nasal cycle.5 They found on T,-weighted MRI that during the congested phase, there was an increased signal intensity in the turbinates, in the mucosa of the lateral nasal wall, in the nasal septum, in the sphenoethmoidal recess, and, interestingly, in the ethmoid sinus. Zinreich et a1 used MRI to conduct a follow-up study of the nasal cycle.6 They compared the cyclic changes with sinus pathology. Again, they found that cyclic changes were limited to the mucosa of the turbinates, the nasal septum, the nasal cavity floor, and, again, in the ethmoid sinus. They concluded that these cyclic changes may be confused with inflammatory disease.
Materials and Methods
We reviewed the MRI scan plates of 3 men and 2 women who had been previously enrolled in another study.'A115 subjects were healthy, paid, adult volunteers. They were interviewed and examined, and were found to nasonex NASONEX~is the only prescription nasal spray that has a prophylaxis indication for the nasal symptoms of seasonal allergic rhinitis.
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Imaging was performed before and after the administration of 0.05% oxymetazoline Hel long-acting topi-
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ca l nasal decongestant spray (fig ures 1-4 ) . Fifte en minut es was allowe d for the decongestant to take effect. Care was taken not to move the subjec t durin g this period . The post-decongestant MRI sca ns were then perform ed and film ed without changing the window co ntras t or other setti ngs . The MRI plates were then reviewed. We divided the nasal cavity into four genera l areas:
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Results
In the pre-decongested state, the MRI showed swelling of the mucosal component of the turbinates and the septum, The local application of oxymetazoline brought about a marked shrinking of the inferior turbinates and significant improvement in the middle turbinates and the septum (table) . Our study showed that the greatest mean decrease in mucosal size took place in the entire (anterior, middle, and posterior) inferior turbinate (mean score: 4). Significant degrees of shrinkage were also seen in the posterior portion of the middle turbinate (mean score: 2.8), in the middle portion of the middle turbinate (mean score: 2.7), and in the anterior septum (mean score: 2.7), Lesser degrees of shrinkage were seen in the superior septum (mean score : 1.6) and in the posterior septum (mean score: 1.4). The degree of change was negligible in the nasal valve (mean score : a,S) and in the uncinate process (mean score: 0.4).
Discussion
In this study , we wished to identify with MRI the location and relative amount of erectile tissues in the nose, The ability of tissue to become erect in the nasal mucosa is dependent on the activity of capacitance vessels.' These sinusoids consist of networks of large, tortuous, valveless , anastomosing veins. Their blood volume fluctuates in response to neural, mechanical, thermal, allergic, psychological, and chemical stimulation, As they expand and shrink, they alter the caliber of the air passages and, consequently , the speed and volume of airflow.' One obstacle we faced in interpreting these MRI scans was that it was difficult to assess the relative post-decongestion change in those areas that were not very congested initially, Volume 78, Number 3
Our study reaffirms the earlier findings by Cole et aI, who detected on CT that erectile nasal tissue is located in the middle turbinate, the anterior septum, and the body of the inferior turbinate. " However, our study goes beyond those findings in showing that the inferior turbinate contains erectile tissue throughout most of its length , not only in its middle portion. In fact, the greatest proportion of erectile tissue seems to be located in the inferior turbinate, as evidenced by changes with decongestion on MRI. We agree with Cole's conclusion that because turbinate swell-.ingdiminishes so rapidly, it seems reasonable to assume that the primary cause of this swelling is an increase in vascular blood volume rather than edema.
Our finding that the greatest mean change in the septum took place in its anterior portion correlates with the results of a study by Saunders et al. 8 Using MRI, they found that there is considerable variation in the thickness of the nasal septum. In their subjects, the septum was thickest anterosuperiorly and thinnest inferiorly, Saunders and colleagues reported that the site of maximum septal thickness was in the area of the nasal valve , while the thinnest area was opposite the inferior turbinates, They presented other interesting data regarding the nasal septum as well.
Saunders et al also validated the accuracy of MRI by reporting that 94% of theirMkl measurements were within a,s mm of those taken during cadaver dissection.
It is interesting to note that in using an immunostain for the endothelial marker CD 31, they were not able to find any evidence of cavernous tissue , although they did find a considerable amount of vascul ar tissue. Their conclusion that there was no cavernous tissue may be flawed because they used cadaver septum, which may not show the cavernous sinusoids on histologic section . Cole et al 165 NG, RAMS EY, COR EY also cited stud ies showing the presence of cavernous tissue s in cada vers in the septum and in the middle and inferior turbinates.'
Conclusion
We conclude that the cavernous tissues of the nose are located in the inferior turbinate, middle turbinate, and the sept um. The most significant of these would seem to be the inferior turbi nate and the area around the anterior sept um where the nasal valve is located.
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